Status:
COMPLETED
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Lead Sponsor:
University of Arkansas
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.
Detailed Description
Recently, laboratory research found that thalidomide can inhibit the formation of new blood vessels that are necessary for the growth and spread of cancer. In order to grow and increase in size, tumor...
Eligibility Criteria
Inclusion
- Patients must have a diagnosis of Multiple myeloma with poor hematopoietic reserve (platelet count \<100,000 OR inability to collect adequate PBSC to support autologous transplant (4X106 CD34+cells/kg OR WBC \<2,000)
- Patients must not be eligible for UARK 98-035
- Patients must be at least 6 weeks beyond previous chemotherapy
- All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines
Exclusion
- Prior bisphosphonate therapy within 30 days prior to study entry
- Serum creatinine \> 5 mg/dl, ascites, or serum direct bilirubin \> 2.5 mg/dl
- Prior plicamycin or calcitonin within 2 weeks of study entry
- Severe cardiac disease, unstable thyroid disease, or epilepsy
Key Trial Info
Start Date :
March 1 1998
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00083408
Start Date
March 1 1998
End Date
May 1 2005
Last Update
July 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences/MIRT
Little Rock, Arkansas, United States, 72205